ResMed (RMD) Expected to Announce Earnings on Thursday

ResMed (NYSE:RMD) is expected to post its Q4 2025 quarterly earnings results after the market closes on Thursday, July 31st. Analysts expect ResMed to post earnings of $2.47 per share and revenue of $1.33 billion for the quarter.

ResMed Price Performance

RMD opened at $278.07 on Wednesday. ResMed has a 12-month low of $199.92 and a 12-month high of $278.10. The company has a current ratio of 3.41, a quick ratio of 2.49 and a debt-to-equity ratio of 0.12. The business’s fifty day simple moving average is $254.71 and its 200-day simple moving average is $239.43. The company has a market capitalization of $40.77 billion, a price-to-earnings ratio of 31.21, a PEG ratio of 1.70 and a beta of 0.77.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 945 shares of the stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $255.49, for a total value of $241,438.05. Following the completion of the sale, the director directly owned 68,273 shares in the company, valued at approximately $17,443,068.77. This trade represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Witte Jan De sold 2,000 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $243.47, for a total value of $486,940.00. Following the completion of the sale, the director owned 5,806 shares of the company’s stock, valued at approximately $1,413,586.82. This trade represents a 25.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,013 shares of company stock worth $7,238,913. 0.71% of the stock is owned by insiders.

Institutional Investors Weigh In On ResMed

An institutional investor recently raised its position in ResMed stock. Jones Financial Companies Lllp raised its holdings in ResMed Inc. (NYSE:RMD) by 52.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,882 shares of the medical equipment provider’s stock after buying an additional 994 shares during the quarter. Jones Financial Companies Lllp’s holdings in ResMed were worth $645,000 at the end of the most recent reporting period. 54.98% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Piper Sandler dropped their price target on ResMed from $260.00 to $248.00 and set a “neutral” rating on the stock in a research report on Thursday, April 24th. Mizuho raised their price objective on ResMed from $250.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 16th. KeyCorp set a $274.00 price objective on ResMed in a research report on Thursday, April 24th. Royal Bank Of Canada raised ResMed from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $255.00 to $294.00 in a research report on Tuesday, July 15th. Finally, JPMorgan Chase & Co. raised their price objective on ResMed from $286.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, April 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $263.00.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.